Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAN-RSV: Pragmatic Randomized Trial of Abrysvo to Prevent RSV Hospitalizations in Adults
2024-516600-42-00Phase 4Authorised
- Sponsor
- Gentofte Hospital
- Start
- Oct 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised trial of RSVpreF vaccine in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Gentofte Hospital. Primary endpoint: Hospitalization for RSV-related respiratory tract disease. Planned start Oct 2024; status: authorised.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2024-516600-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516600-42-00.